Shield Therapeutics plc announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was GBP 481,000 compared to GBP 8.919 million a year ago. Operating loss was GBP 7.643 million compared to operating Income of GBP 2.393 million a year ago. Net loss was GBP 7.283 million compared to net income of GBP 3.124 million a year ago. Basic loss per share from continuing operations was GBP 0.04 compared to basic earnings per share from continuing operations of GBP 0.03 a year ago.